Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults.
M Guzmán-Fulgencio, R Caballero, B Lara...
https://pubmed.ncbi.nlm.nih.gov/27939406/Actively Recruiting
Led by Inmunotek S.L. · Updated on 2025-05-13
180
Participants Needed
27
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of subcutaneous immunotherapy in patients aged 12 to 65 who have rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, and who are sensitive to cupressaceae and grass pollen. This phase 3, multicenter, randomized, double-blinded, placebo-controlled trial aims to better understand treatment options for allergy symptoms related to these pollens. Participants will be randomly assigned to one of three groups two groups receiving different doses of a purified and polymerized allergen extract from grasses and cupressaceae mixed with aluminum hydroxide, and one placebo group receiving a similar solution without active ingredients. The treatment will be given by subcutaneous injections and will last for 18 months. The study will monitor symptoms and medication use during the specific pollen seasons for cupressaceae January to March and grasses May to June. Throughout the trial, participants will record their symptoms and medication intake using an electronic diary via a smartphone. Researchers will assess combined symptom and medication scores as the primary outcome, along with various secondary measures such as symptom-free days, medication-free days, asthma and rhinitis symptom scores, quality of life, immunological parameters, and safety. The total participation time for each subject is 18 months, during which their health and response to treatment will be closely monitored.
CONDITIONS
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
M
Miguel Casanovas, MD PhD
R
Raquel Caballero
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Inmunotek S.L.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 18 months
Participants receive subcutaneous immunotherapy with either active treatment or placebo for allergy against cupressaceae and grasses.
Regular visits for treatment administration and monitoring
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
M Guzmán-Fulgencio, R Caballero, B Lara...
https://pubmed.ncbi.nlm.nih.gov/27939406/Raquel Caballero, Alicia Grau, Gracia Javaloyes...
https://pubmed.ncbi.nlm.nih.gov/33498057/Inmunotek S.L.
Lead Sponsor